XNK Therapeutics has actively participated in several public-private partnerships to develop its technology platform. The main collaborating partners have been Karolinska Institutet, Karolinska University Hospital, and the Royal Institute of Technology.
XNK Therapeutics is currently participating in three public-private partnerships. They have allowed the company to develop its technology within the competence center AdBIOPRO, as well as its business model within the SWElife-ATMP organization. The latest public-private partnership, the one with the competence center NextGenNK, will allow XNK Therapeutics to build further on the clinical development of its leading investigational drug candidate, CellProtect. XNK Therapeutics is always open for, and actively looking, collaboration partners.
Please contact our CEO Johan Liwing (firstname.lastname@example.org) for discussing research collaborative ideas.